New & Noteworthy

March 2024

Bivalirudin for Injection


Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, has launched bivalirudin for injection. The medication features differentiated packaging and labeling to support accurate medication selection, as a therapeutic equivalent generic for Angiomax for injection (bivalirudin) approved by the US FDA. Bivalirudin for injection is indicated as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.

Request More Information

Current Issue